Medically reviewed by Drugs.com. Last updated on Oct 13, 2018.
(ten A pa nor)
- Tenapanor Hydrochloride
- Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor
Use: Labeled Indications
Irritable bowel syndrome with constipation: Treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
Patients <6 years of age; known or suspected mechanical GI obstruction
There are no known significant interactions.
>10%: Gastrointestinal: Diarrhea (15% to 16%)
1% to 10%:
Central nervous system: Dizziness (2%)
Gastrointestinal: Flatulence (3%), severe diarrhea (3%), abdominal distension (2% to 3%), abnormal bowel sounds (<2%)
Hematologic & oncologic: Rectal hemorrhage (<2%)
ALERT: U.S. Boxed WarningRisk of serious dehydration in pediatric petients
Tenapanor is contraindicated in patients <6 years; in nonclinical studies in young juvenile rats, administration of tenapanor caused deaths presumed to be due to dehydration; avoid use of tenapanor in patients 6 years to <12 years; the safety and effectiveness of tenapanor have not been established in patients <18 years.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.